Advances in Treatment of Frontotemporal Dementia
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
In this review, the authors explored the clinical features of frontotemporal dementia (FTD), focusing on treatment. The clinical features of FTD are unique, with disinhibition, apathy, loss of empathy, and compulsions common. Motor changes occur later in the illness. The two major proteins that aggregate in the brain with FTD are tau and TDP-43, whereas a minority of patients aggregate FET proteins, primarily the FUS protein. Genetic causes include mutations in MAPT, GRN, and C9orf72. There are no medications that can slow FTD progression, although new therapies for the genetic forms of FTD are moving into clinical trials. Once a diagnosis is made, therapies should begin, focusing on the family and the patient. In the setting of FTD, families experience a severe burden associated with caregiving, and the clinician should focus on alleviating this burden. Advice around legal and financial issues is usually helpful. Careful consideration of environmental changes to cope with abnormal behaviors is essential. Most compounds that have been used to treat dementia of the Alzheimer’s disease type are not effective in FTD, and cholinesterase inhibitors and memantine should be avoided. Although the data are scant, there is some evidence that antidepressants and second-generation antipsychotics may help individual patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This therapeutic impasse extends beyond AD to other major cognitive disorders, including LBD (Agarwal et al., 2024), FTD (Magrath Guimet et al., 2022), and PDD (Szeto and Lewis, 2016), for which no disease-modifying therapies exist.”
From Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine (2026) · cites this paper as Magrath Guimet et al., 2022
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS
Mori, K., Weng, S.-M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H. A., Cruts, M., Van Broeckhoven, C., et al. (2013) · Science · doi:10.1126/science.1232927 · Cited by 1,277
A harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R. A., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. Y. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,017
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688
Self-citation
Research works printed but not linked: 6
- Seeley WW, 2019, Continuum (Minneap Minn), 25, 76
- Ikeda M, 1995, Seishin Shinkeigaku Zasshi, 97, 179
- Forbes D, 2014, Cochrane Database Syst Rev, 26, CD003946
- 2020, AHFS Drug Information 2020
- Ishikawa H, 2006, Seishin Shinkeigaku Zasshi, 108, 1029
- Engelborghs S, 2004, J Neurol Neurosurg Psychiatry, 75, 1080
Cited by
Exosomes in brain diseases: Pathogenesis and therapeutic targets
Si, Q., Wu, L., Pang, D., & Jiang, P. (2023) · MedComm · doi:10.1002/mco2.287 · Cited by 69
Sidoryk‐Wȩgrzynowicz, M., Adamiak, K., & Strużyńska, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212448 · Cited by 28
Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 30
Defining repetitive behaviours in frontotemporal dementia
Restrepo-Martínez, M., Ramirez-Bermudez, J., Chacon-Gonzalez, J., Ruiz-Garcia, R., Malik, R., & Finger, E. (2024) · Brain · doi:10.1093/brain/awad431 · Cited by 15
Seritan, A. L. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231164357 · Cited by 15
Metadata
- Authors
- Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L.
- Affiliations
- Global Brain Health Institute, University of California, San Francisco (all authors); Institute of Neuroscience, Trinity College, Dublin (all authors); Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Instituto Neurológico Fleni, Buenos Aires (Magrath Guimet); Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco (Miller); and Department of Medical Sciences, Pontifical Xaverian University Cali, Cali, Colombia ...
- University of California, San Francisco (US)
- ORCID
- Miller, Bruce L.
- Venue
- The Journal of Neuropsychiatry and Clinical Neurosciences
- Published
- 2022-10
- Volume
- 34
- Issue
- 4
- Pages
- 316-327
- ISSN
- 0895-0172 (ISSN-L)
- 1545-7222
- OpenAlex
- W4280524497
- Cited by
- 52
- References
- 128
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 18 · 2023: 8
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal dementia, disinhibition, apathy, loss of empathy, compulsive behavior, tau protein, TDP-43, FUS protein, MAPT mutations, GRN mutations, C9orf72, family caregiver burden, behavior management, cholinesterase inhibitors, memantine, antidepressants, atypical antipsychotics, dementia treatment
- MeSH terms
- C9orf72 Protein, Cholinesterase Inhibitors, DNA-Binding Proteins, Humans, Memantine, Mutation, RNA-Binding Protein FUS, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Treatment of Frontotemporal Dementia. https://app.cochat.ai/papers/10.1176/appi.neuropsych.21060166
- The paper
- Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022). Advances in Treatment of Frontotemporal Dementia. The Journal of Neuropsychiatry and Clinical Neurosciences. https://doi.org/10.1176/appi.neuropsych.21060166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.